Summary
Corteva, Inc. reported a net sales increase of 6% to $4.88 billion for the first quarter of 2023, driven by a 14% price increase, partially offset by a 4% volume decrease and a 5% unfavorable currency impact. Net income increased to $595 million, or $0.83 per diluted share, compared to $564 million, or $0.78 per diluted share, in the prior year's quarter. The company completed significant acquisitions of Stoller Group, Inc. and Quorum Vital Investment, S.L. (Symborg) for a combined $1.6 billion, strengthening its biologicals and microbiological technologies portfolio. Corteva also updated its full-year 2023 guidance, raising its net sales and Operating EBITDA expectations to reflect the impact of these acquisitions.
Financial Highlights
53 data pointsBeta
Financial Statements
Beta
| Revenue | $4.88B |
| Cost of Revenue | $2.77B |
| Gross Profit | $2.11B |
| R&D Expenses | $316.00M |
| SG&A Expenses | $726.00M |
| Net Income | $595.00M |
| EPS (Basic) | $0.84 |
| EPS (Diluted) | $0.83 |
| Shares Outstanding (Basic) | 712.90M |
| Shares Outstanding (Diluted) | 716.20M |
Key Highlights
- 1Net sales increased 6% to $4.88 billion in Q1 2023 compared to Q1 2022.
- 2Diluted Earnings Per Share (EPS) rose to $0.83 from $0.78 year-over-year.
- 3Acquisition of Stoller Group and Symborg completed for $1.6 billion to enhance biologicals and microbiological offerings.
- 4Operating EBITDA improved by 18.5% to $1.23 billion compared to the prior year.
- 5The company raised its full-year 2023 sales and Operating EBITDA guidance.
- 6Shareholder returns through dividends and share repurchases totaled $360 million in Q1 2023.
Frequently Asked Questions
Corteva's revenue growth was primarily driven by a 14% increase in price, reflecting its 'price for value' strategy and efforts to recover higher input costs. This was partially offset by a 4% decrease in volume and a 5% unfavorable currency impact.
The acquisitions of Stoller and Symborg, completed on March 1, 2023, were significant strategic moves to bolster Corteva's biologicals and microbiological technologies. While their operating results did not materially impact the Q1 2023 financial statements due to their recent completion, they were factored into the raised full-year 2023 financial guidance, contributing to the increased sales and Operating EBITDA expectations.
Corteva has updated its full-year 2023 guidance, now expecting net sales between $18.6 billion and $18.9 billion, and Operating EBITDA between $3.55 billion and $3.75 billion. Operating Earnings Per Share is projected to be between $2.80 and $3.00. This updated outlook incorporates the contributions from the recent acquisitions.
In the first quarter of 2023, Corteva returned approximately $360 million to shareholders through common stock dividends and share repurchases. The company completed its 2021 $1.5 billion share repurchase program during this quarter and continues to execute its $2 billion share repurchase program authorized in September 2022.